Phase I
Migraine headaches can be reduced in frequency and severity by atogepant, an oral therapy developed by AbbVie. So migraines will be gone sooner than we think.
BioSpace continues to take a look at some of the data that will be shared at the 2021 ASCO meeting. Here are some of them.
Heading into the U.S. Memorial Day holiday weekend and the official start of summer, it was a moderately busy week for clinical trial news. Take a look.
Determined to take its next-generation engineered cell therapies to the next level, BlueRock teams up with Senti Biosciences with futuristic medicines in mind.
This is the second IND to come out of the two companies’ collaboration. They will initiate a Phase I trial of the drug in cardiometabolic diseases.
The company says it plans to file an IND for the candidate, dubbed CFT8919, by the middle of next year.
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
This is after Larimar reported deaths in the highest dose levels of a nonhuman primate toxicology study.
Emergent said the vaccine candidate against the mosquito-borne illness showed an increase in immune response as measured by anti-chikungunya virus SNA.
Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.
PRESS RELEASES